Pfizer Inc. (PFE) along with BioNTech SE (BNTX) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency's (EMA) has rendered a positive opinion recommending marketing authorization for their updated formulation of the mRNA-based COVID-19 vaccine, Comirnaty, which targets the currently circulating KP.2 strain of the Omicron JN.1 lineage.The CHMP recommended marketing approval for Pfizer/BioNTech’s Omicron KP.2-adapted COVID-19 vaccine for individuals aged six ...

Group 1 - JR Research is recognized as a Top Analyst by TipRanks and Seeking Alpha for his expertise in Technology, Software, Internet, Growth, and GARP [1][2] - The investment strategy focuses on identifying attractive risk/reward opportunities with robust price action to generate alpha above the S&P 500 [1] - The approach combines price action analysis with fundamentals investing, avoiding overhyped stocks while targeting battered stocks with recovery potential [1] Group 2 - The investing group Ultimate Growth Investing specializes in identifying high-potential opportunities across various sectors with a focus on strong growth potential and contrarian plays [2] - The investment thesis typically has an 18 to 24 month outlook for realization [2] - The group aims to capitalize on growth stocks with robust fundamentals, buying momentum, and turnaround plays at attractive valuations [2]

Pfizer Inc. (PFE, Financial) rose to prominence during the Covid-19 pandemic for its rapid development of a vaccine and antiviral therapy, establishing a household name in the process. As the pandemic faded, the stock lost over 50% of its value from its all-time high. However, the company legacy goes far beyond this. With a long history of pioneering invention, the pharmaceutical giant has continually provided life-saving solutions in fields such as oncology and cardiovascular care. Further, it has been mak ...

Upon authorization by the European Commission, the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and older Data demonstrate that the Omicron KP.2-adapted COVID-19 vaccine generates a substantially improved response against multiple circulating Omicron JN.1 sublineages as did the Omicron JN.1-adapted COVID-19 vaccine authorized by the European Commission in July 2024Doses will be ready to ship to applicable European Union member states as soon as possible upon Euro ...

Core Viewpoint - Pfizer's stock has shown a significant recovery, rising 7.3% over the past three months, outperforming both the industry and the S&P 500, despite previous struggles due to declining COVID-related product sales [1][2]. Sales Performance - Pfizer's sales from COVID products, Comirnaty and Paxlovid, have sharply declined in 2023, with a projected further decrease in 2024, estimating combined revenues of $8.5 billion compared to $12.5 billion in 2023 [3]. - Overall sales fell 42% in 2023 from a record high of $100 billion in 2022, raising concerns about long-term growth drivers beyond COVID-related products [2]. Growth Drivers - In 2023, Pfizer achieved a record number of FDA approvals, with nine new medicines and vaccines expected to drive future growth [4]. - Non-COVID operational revenues improved in the first half of 2024, supported by key products like Prevnar, Vyndaqel, and Eliquis, as well as new launches and acquisitions, including those from Seagen [4][5]. - Pfizer anticipates a revenue CAGR of approximately 6% from 2025 to 2030, bolstered by its late-stage pipeline and newly acquired products [4]. Oncology Position - Pfizer has a strong position in oncology, with oncology sales accounting for over 26% of total revenues and growing 23% on an operational basis in the first half of 2024 [6]. - The acquisition of Seagen has further strengthened Pfizer's oncology portfolio, with expectations of having eight or more blockbuster oncology medicines by 2030 [6]. Valuation and Earnings Estimates - Pfizer's stock is currently trading at a forward P/E ratio of 10.68, which is lower than the industry average of 19.77 and its own 5-year mean of 11.44, indicating an attractive valuation [7]. - The Zacks Consensus Estimate for earnings per share has increased from $2.39 to $2.62 for 2024 and from $2.75 to $2.85 for 2025 over the past 60 days, reflecting a positive outlook [8][9]. Investment Consideration - Pfizer is seen as gradually recovering from previous downturns, with non-COVID drugs and new product contributions driving growth [10]. - The company maintains a dividend yield of around 6% and expects to achieve savings of $4 billion in 2024 through cost cuts and restructuring [10]. - Rising earnings estimates suggest an optimistic outlook for Pfizer's growth potential, making it a candidate for investment at its current valuation [10].

The company's best days as a top pandemic vaccine supplier might be over, but it still has enough potential to be compelling.It was a rock star during the coronavirus pandemic, but Pfizer (PFE 2.73%) hasn't been the most exciting company in 2024. Its stock has become something of a value play, at least according to one analyst who released a fresh research note based on meetings with company management. He feels the stock has upside potential that's comfortably in the double-digit percentages. Here's why.An ...

KEY TAKEAWAYSPfizer said this weekend that a drug aimed at helping cancer patients losing appetite and muscle mass showed positive results in a Phase 2 trial.The pharma giant said ponsegromab will start late-stage trials next year. The drug aims to treat cancer cachexia, the life-threatening wasting condition that often affects patients with the disease. Pfizer (PFE) said this weekend that a drug aimed at helping cancer patients losing appetite and muscle mass showed positive results in a Phase 2 trial. The ...

Core Viewpoint - Pfizer's high dividend yield of 5.7% is attractive but raises concerns about sustainability due to an alarming payout ratio of 436% [1][4][5] Group 1: Company Overview - Pfizer is a global pharmaceutical leader with over 350 marketed medicines and 113 experimental candidates in clinical trials, operating in more than 200 countries [2] - The company's stock has declined 52% from its three-year high, primarily due to a slump in COVID-19 sales [2] Group 2: Valuation and Market Position - Pfizer's shares are trading at 9.6 times projected earnings for 2026, indicating a significant discount compared to the pharmaceutical sector [3] - The company's high dividend yield and strong market position create a compelling value proposition for long-term investors [3] Group 3: Dividend Sustainability Concerns - The payout ratio of 436% is significantly higher than the typical threshold of 75%, raising alarms about the sustainability of the dividend [4][5] - The average payout ratio among Pfizer's peers is 141%, highlighting the severity of Pfizer's situation [5] Group 4: Management's Commitment and Future Prospects - Pfizer's management has reaffirmed its commitment to maintaining and growing the dividend, supported by a 15-year streak of consecutive increases [6] - A cost-saving plan targeting $4 billion in net savings aims to improve free cash flows and support short-term dividend sustainability [6] - The pipeline includes potential blockbuster cancer drugs that could significantly enhance revenue and earnings, potentially bringing the payout ratio closer to its historical average of around 50% [7] Group 5: Market Sentiment and Investment Consideration - Despite a bearish sentiment reflected in a 14% decline in shares over the past year, management's commitment and promising drug pipeline suggest potential for a turnaround [5][8] - Pfizer's shares are trading at a steep discount relative to many peers, providing a margin of safety for investors [8] - Monitoring the company's financial health and dividend coverage remains crucial for investors considering high-yield opportunities [8]

Pfizer's experimental drug for a common, life-threatening condition that causes cancer patients to lose their appetite and weight showed positive results in a midstage trial, the drugmaker said Saturday. Patients with the condition, called cancer cachexia, who took Pfizer's treatment saw improvements in body weight, muscle mass, quality of life and physical function, according to the drugmaker. The results could pave the way for the drug, a monoclonal antibody called ponsegromab, to become the first treatme ...

Blister packets each containing a dose of PAXLOVID prescription medicine for a patient's Covid-19 ... [+] viral infection are arranged for a photo illustration on September 4, 2024 in Los Angeles, California. (Photo by Patrick T. Fallon / AFP) (Photo by PATRICK T. FALLON/AFP via Getty Images)AFP via Getty ImagesGiven its better valuation, we believe that Pfizer stock (NYSE: PFE) is currently a better pick than its industry peer – AbbVie stock . PFE stock trades at a much lower multiple of 11x forward, versu ...